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Polypoidal choroidal vasculopathy (PCV) is character-
ized by a branching vascular network with polypoidal 
shaped choroidal vascular lesions that result in subretinal 
leakage, subretinal hemorrhage, and pigment epithelial de-
tachment [1-4]. When pathologic changes associated with 
PCV extend to the subfoveal area, visual prognosis may be 
poor. Sho et al. [3] have found severe vision loss caused by 
persistent serous detachment, atrophy of retinal pigment 
epithelium (RPE), and submacular hemorrhage in 34.5% 
(38 of 110 eyes) of PCV patients.
There is no widely accepted and effective method of 
treatment for PCV. Photodynamic therapy (PDT) with 
verteporfin or intravitreal injection of anti-vascular endo-
thelial growth factor (VEGF) has recently been adminis-
tered for treatment of PCV eyes, and encouraging results 
have been reported [5-10].
The pathogenesis of PCV is not fully understood. How-
ever, VEGF may have a role in pathogenesis. Compared 
with normal controls, VEGF concentrations in the aqueous 
were found to be markedly increased in PCV eyes [11], 
and there is a strong expression of VEGF in PRE cells of 
PCV specimens [12]. These reports support the use of anti-
VEGF treatment in PCV eyes.
Ranibizumab is a humanized, anti-VEGF antibody 
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Purpose: To compare the effectiveness of intravitreal injections of bevacizumab and ranibizumab in patients 
with treatment-naive polypoidal choroidal vasculopathy (PCV).
Methods: Records from 106 consecutive patients who received intraviteral bevacizumab (n = 58, 1.25 mg) or 
ranibizumab (n = 52, 0.5 mg) for treatment of PCV were retrospectively reviewed. After three initial monthly 
loading injections, injection was performed as needed. The main outcome measures included best-corrected 
visual acuity (BCVA), foveal central thickness (FCT) as assessed by spectral domain optical coherence to-
mography, and the changes in polypoidal lesions based on an indocyanine green angiography.
Results: The average number of injections was 3.31 ± 1.25 in the bevacizumab group and 3.44 ± 0.92 in the 
ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline to 6 months 
after injection improved by 0.17 in the bevacizumab group (p = 0.03) and by 0.19 in the ranibizumab group (p 
= 0.01). Average FCT decreased from 322 ± 62.48 μm to 274 ± 40.77 μm in the bevacizumab group (p = 0.02) 
and from 338 ± 50.79 μm to 286 ± 36.93 μm in the ranibizumab group (p = 0.02). Polyp regression rate was 
20.7% (12 of 58 eyes) in the bevacizumab group and 21.2% (11 of 52 eyes) in the ranibizumab group. There 
was no statistically significant difference between groups in BCVA improvement achieved, FCT improvement 
achieved, and polyp regression rate between groups.
Conclusions: Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilizing of visual 
acuity, macular edema, and regression of polypoidal complex in PCV eyes over the short term. 
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that inhibits all forms of biologically active VEGF-A [13]. 
Treatment with ranibizumab appears to significantly de-
crease bleeding and exudation in PCV [10]. Bevacizumab (a 
humanized, full-length anti-VEGF antibody) also appears 
to have a treatment effect in PCV eyes [8,9]. Kokame et 
al. [12] reported that continuous, monthly intravitreal ra-
nibizumab injections were well tolerated in PCV patients. 
Additionally, patients also showed stabilized vision and 
decreased macular edema. 
Differences in the therapeutic effect between beva-
cizumab and ranibizumab in neovascular age-related 
macular degeneration are controversial. A large head-to-
head clinical trial sponsored by the National Eye Institute 
for evaluation of the efficacy of ranibizumab and bevaci-
zumab is ongoing and a more definite result is anticipated 
in the future [13]. However, to the best of our knowledge, 
there have been no reports about the differences between 
bevacizumab and ranibizumab for treatment of PCV. The 
purpose of this current study is to determine whether 
or not there are differences in short-term effectiveness 
between bevacizumab and ranibizumab for treatment of 
PCV.
Materials and Methods
After obtaining approval by the institutional review 
board, a retrospective medical record review was conduct-
ed using records from 106 consecutive patients (110 eyes) 
who were treated with intravitreal anti-VEGF agents for 
PCV at Kim’s Eye Hospital, Konyang University College 
of Medicine from November 2008 to June 2010. 
Patients were included if they met all of the following 
criteria: 1) confirmation of PCV with fluorescein angiog-
raphy (FA) and indocyanine green angiography (ICGA) 
performed using a confocal laser scanning system (HRA-
2; Heidelberg Engineering, Dossenheim, Germany) at the 
first visit. We only included patients whose ICGA showed 
a branching vascular network with polypoidal shaped cho-
roidal vascular lesions, 2) patients who were treated with 
only one type of anti-VEGF agent (either bevacizumab 
or ranibizumab), and 3) a minimum follow-up period of 6 
months.
Exclusion criteria were the following: 1) combination 
therapy of more than one anti-VEGF agent, 2) prior treat-
ment with PDT, 3) pathologic myopia, 4) idiopathic choroi-
dal neovascularization (CNV), 5) other secondary CNV, 
6) other ocular disease that could affect visual acuity, 7) 
trauma during the study or in the fellow eye, 8) aphakia, or 
9) previous vitreoretinal surgery.
Treatment and re-treatment protocols were the same 
for both groups of patients. Evidence of PCV with recent 
visual deterioration was an indication for treatment. We 
performed three consecutive, monthly-loading dose injec-
tions in every patient. After the initial loading injections 
at the time of diagnosis, retreatment for each patient was 
planned as a ‘retreat as needed’ protocol. Anti-VEGF 
agents were re-injected on a monthly basis if objective 
visual deterioration of more than two lines, persistent 
exudates and hemorrhage, or evidence of an active PCV 
lesion were observed on FA, ICGA, or optical coherence 
tomography (OCT), were observed. Best-corrected visual 
acuity (BCVA) was obtained every one or two months 
using the Snellen chart. Patients also underwent an oph-
thalmic examination, including a slit-lamp evaluation and 
fundus examination, as well as OCT (Spectral OCT/SLO; 
OTI Ophthalmic Technologies Inc., Miami, FL, USA), FA, 
ICGA, or a combination thereof. 
Foveal center thickness (FCT) was assessed by OCT 
using six diagonal fast and slow 6-mm scans. Retinal 
thickness of the 1-mm central retina was obtained by a 
fast macular scan. Only well-centered scans without overt 
algorithm failure messages were selected for analyses.
Intravitreal antivascular endothelial growth factor in-
jection
The off-label nature of the treatment and its potential 
risks and benefits were discussed in detail with all patients, 
and signed informed consent was obtained from all pa-
tients. Patients received 1.25 mg of bevacizumab or 0.5 mg 
of ranibizumab. Prior to administration of the injection, 
topical anesthesia was applied, and 10% povidone-iodine 
was used for scrubbing of eyelid and lashes. Following the 
application of povidone-iodine eyedrops (1.25%), a sterile 
lid speculum was placed into place. Intravitreal injection 
was performed with a 30-gauge needle at 3.5 to 4 mm 
from the inferotemporal limbus. Pressure was applied to 
the injection site using a sterile cotton swab, for 1 minute. 
All patients were instructed to apply antibiotic eye drops 
for one week.
Statistical analysis
SAS (SAS Institute Inc., Cary, NC, USA) was used for 
all analyses. Frequencies were compared between treat-
ment groups using chi-square tests. The changes in BCVA 
and FCT between baseline and the 6 month follow-up 
were analyzed with a 1-tailed, paired t-test. For continuous 
variables, medians for baseline, final values, change, and 
percent change were compared between bevacizumab and 
ranibizumab treatment groups using a t-test or a Wilcoxon 
rank sum tests. A p-value of less than 0.05 was considered 
significant.
Results
Patient demographics and comparisons of data at base-
line are summarized in Table 1. Bevacizumab-treated and 159
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ranibizumab-treated patients had similar baseline charac-
teristics for age, sex, distribution of baseline BCVA, loca-
tion of polyps, or FCT (Table 1). All patients were Korean, 
and no systemic adverse events were recorded for any of 
the patients treated with intravitreal injection. No compli-
cations, including issues such as endophthalmitis, traumat-
ic lens injury, or retinal detachment, were associated with 
intravitreal injections.
The average number of injections was 3.31 ± 1.25 in the 
bevacizumab group and 3.44 ± 0.92 in the ranibizumab 
group. At baseline, the mean BCVA (±standard deviation, 
SD) in the bevacizumab and ranibizumab groups was 0.92 
(±0.54; Snellen equivalent, 20 / 166) and 0.96 (±0.57; Snel-
len equivalent, 20 / 182), respectively. Six months after 
treatment, both bevacizumab and ranibizumab groups 
had significantly increased BCVA to 0.74 (±0.51; Snel-
len equivalent, 20 / 110; p = 0.03) and 0.78 (±0.43; Snellen 
equiva lent, 20 / 120; p = 0.01) respectively (Table 2, Figs. 1 
and 2). There was no statistically significant difference in 
BCVA improvement achieved between these two groups (p 
= 0.83). Six (10.3%) eyes out of 58 eyes in the bevacizumab 
group and 5 (10.0%) eyes (10.0%) out of 52 eyes in the ra-
nibizumab group showed a loss of ≥3 lines of visual acuity. 
In either group, no significant difference in proportion of 
more than 3 lines of visual acuity loss was observed (p = 
0.82). There was also no significant difference in propor-
tion of more than 3 lines of visual acuity gain in either 
group (p = 0.12) (Table 3).
Mean (±SD) FCT at baseline in the bevacizumab and 
ranibizumab groups was 322 (±62.48) μm and 338 (±50.79) 
μm, respectively. Six months after treatment, FCT of both 
the bevacizumab and ranibizumab groups were signifi-
cantly decreased to 274 (±40.77) μm (p = 0.02) and 286 
(±36.93) μm (p = 0.02), respectively. There was no statisti-
cally significant difference in reduction of FCT in either 
group (p = 0.74) (Table 2). Twenty four of 58 eyes (41.4%) 
in the bevacizumab-treated group showed a decrease of 
more than 10% from baseline FCT. Thirty one eyes out of 
52 eyes (59.6%) in the ranibizumab-treated group showed a 
decrease of more than 10% from baseline FCT. No signifi-
cant difference in the proportion of decrease greater than 
10% from baseline FCT was observed in either group (p = 
0.35). However, a greater number for ≥10% decreased FCT 
was observed in the ranibizumab group, and the difference 
was statistically significant (p = 0.02) (Table 3). 
Polyp regression was found in 12 of 58 eyes (20.7%) in 
the bevacizumab group and in 13 of 52 eyes (25.0%) in 
the ranibizumab group. No significant difference in polyp 
regression rate was observed between groups (p = 0.87) 
(Table 3).
Discussion 
PCV is increasingly recognized as a major cause of vi-
sion loss throughout the world; however, the incidence of 
PCV is especially high in Asian countries and in Asian 
people throughout the world [14,15]. The most important 
causes of severe visual loss include repeated subretinal 
hemorrhage and leakage from PCV lesions [3], repeated 
injuries resulting in atrophy of RPE, or scar change. Al-
though the pathophysiology of PCV is poorly understood, 
resolving subretinal hemorrhage and decreasing leakage 
from PCV lesions may be an important and reasonable 
approach to stabilize visual acuity. Additionally, VEGF 
Table 1. Bevacizumab and ranibizumab for PCV: patient de-
mographics and comparisons at baseline
Bevacizumab 
(58 eyes of 56 patients)
Ranibizumab 
(52 eyes of 50 patients) p-value
Age (yr)   61.62 ± 10.42   60.22 ± 11.48 0.86
Gender
Male 40 (71.4)   34   (68.0)
Female 16 (27.6)   16   (32.0) 0.77
BCVA (logMAR)
≤0.3 15 (25.9)   9   (17.3)
>0.3 – ≤0.7 24 (41.4)   27   (51.9)
>0.7 20 (34.5)   16   (30.8) 0.91
Location of polyp
Subfoveal 10 (17.2)   10   (19.2)
Juxtafoveal 33 (56.9)   26   (50)
Extrafoveal 15 (20.7)   16   (30.8) 0.93
Vaules are presented as mean ± SD or number (%).
PCV = polypoidal choroidal vasculopathy; BCVA = best-correct-
ed visual acuity; logMAR = logarithm of the minimum angle of 
resolution.
Table 2. Bevacizumab and ranibizumab for PCV: results at 6 months after treatment
BCVA (logMAR) FCT (μm) Mean injections
Month 0 Month 6 p-value Month 0 Month 6 p-value No. at 6 months
Bevacizumab
(58 eyes)
0.92 ± 0.54 0.74 ± 0.51 0.03 322 ± 62.48 274 ± 40.77 0.02 3.31 ± 1.25
Ranibizumab
(52 eyes)
0.96 ± 0.57 0.78 ± 0.43 0.01 338 ± 50.79 286 ± 36.93 0.02 3.44 ± 0.92
PCV = polypoidal choroidal vasculopathy; BCVA = best-corrected visual acuity; logMAR = logarithm of the minimum angle of resolu-
tion; FCT = foveal center thickness.160
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concentrations in the aqueous have been found to be mark-
edly increased in PCV eyes [11], and a strong expression of 
VEGF was observed in PRE cells of PCV specimens [12]. 
Collectively, evidence appears to support the success of 
anti-VEGF treatment for PCV eyes.
Ranibizumab, which is specifically for intraocular use, 
has several theoretical advantages over bevacizumab. 
Ranibizumab is a humanized anti-VEGF antibody that in-
hibits all forms of biologically active VEGF-A [16]; treat-
ment with ranibizumab appears to significantly decrease 
bleeding and exudation in PCV [10,12]. Bevacizumab (a 
humanized full length anti-VEGF antibody) also appears 
to have a treatment effect in PCV eyes [8,9]. Considering 
the molecular weight of each medication (ranibizumab is a 
48-kDa Fab fragment, whereas bevacizumab is a complete 
149-kDa antibody), ranibizumab may be more effective in 
treatment of PCV because of its smaller molecular weight 
and possible deeper penetration to choroidal vascular 
abnormality lesions in those with PCV [15]. Moreover, 
ranibizumab is affinity-matured and may provide bet-
ter VEGF inhibition through stronger molecular binding, 
compared with bevacizumab. In comparison, penetration 
of the neural retina up to the choriocapillaries by intra-
vitreal bevacizumab has been demonstrated [17]. And the 
larger molecular weight of bevacizumab might result in a 
longer duration of action. Therefore, it may be possible that 
the clinical efficacies of these two drugs might differ [18].
In the current study, both drugs significantly improved 
visual acuity in the short term, and showed similar in-
creases in their mean visual acuity from baseline. How-
ever, despite the lack of power to determine small changes 
in visual acuity between bevacizumab and ranibizumab, 
our results revealed a trend toward a greater number for 
≥3-line improvements in the ranibizumab group. Although 
it is uncertain what factors made this difference in visual 
acuity between the two groups, these results showing a 
Table 3. Bevacizumab and ranibizumab for PCV: visual acuity, optical coherence tomography, and indocyanine green angiography 
changes at month 6 after treatment
Bevacizumab-treated eyes out of 58 (%) Ranibizumab-treated eyes out of 52 (%) p-value
BCVA changes at month 6 
Gained ≥3 lines   11  (19.0)   14  (25.0) 0.12
Lost ≥3 lines   6  (10.3)   5  (10.0) 0.82
FCT changes at month 6
Decreased by 10% or more   24  (41.4)   31  (59.6) 0.02
Increased by 10% or more   8  (13.8)   5  (10.0) 0.35
Polyp regression at month 6
Regression   12  (20.7)   11  (21.2) 0.87
Persistence   46  (79.3)   39  (75.0) 0.78
PCV = polypoidal choroidal vasculopathy; BCVA = best-corrected visual acuity; FCT = foveal center thickness.
Fig. 1. Intravitreal bevacizumab and ranibizumab for polypoi-
dal choroidal vasculopathy: graph showing serial changes in the 
mean logarithm of the minimum angle of resolution (logMAR) 
visual acuity from baseline to month 6 post-treatment. The dif-
ferences in time course between the two groups were not signifi-
cant. There was a significant decrease in logMAR in both groups.
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Fig. 2.  Intravitreal bevacizumab and ranibizumab for polypoidal 
choroidal vasculopathy: graph showing serial changes in optical 
coherence tomography and mean foveal center thickness (FCT) 
from baseline to month 6 post-treatment. The differences in time 
course between the 2 subgroups were not significant. There was a 
significant decrease in FCT in both groups.161
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significantly greater number for ≥10% decreased CFT in 
the ranibizumab group could have an association. 
Macular edema based on FCT significantly improved 
in both groups and showed similar decreases in mean 
FCT from baseline. A similar decrease in macular edema 
was noted after three monthly bevacizumab injections in 
a study by Lai et al. [9]. Additionally, Kokame et al. [12] 
reported improvement in macular edema after 6 monthly 
ranibizumab injections. Findings from these previous re-
ports as well as those of our study collectively suggest that 
short-term continuous anti-VEGF therapy doses do have a 
significant effect in reducing macular edema but not in all 
PCV eyes. In this study, our results revealed a significantly 
greater number of patients who showed ≥10% decrease in 
FCT in the ranibizumab group compared to that in the be-
vacizumab group. It may be that the difference in changes 
of FCT between the two groups resulted from differences 
in penetration ability; ranibizumab may have been more 
anatomically effective than bevacizumab in reducing mac-
ular edema with PCV lesions. Further, these results imply 
that there is a distinct difference in short-term biologic 
activity between bevacizumab and ranibizumab.
The choroidal vascular branching network and polypoi-
dal complexes have been resistant and poorly responsive 
to anti-VEGF therapy with bevacizumab or ranibizumab 
[8,12]. In the Gomi et al. [8] and the Gomi et al. [15] stud-
ies, choroidal vascular abnormalities remained in ten 
of 11 eyes after one to three intermittent injections of 
bevacizumab. Kokame et al. [12] found that polypoidal 
complex decreased in four of 12 eyes (33%) after 6 con-
tinuous monthly ranibizumab injections. In the current 
study, polypoidal lesions appeared to be resistant to both 
anti-VEGF agent, and the polypoidal complex showed a 
decrease in only 12 of 58 eyes (20.7%) in the bevacizumab 
group and 13 of 52 eyes (25.0%) in the ranibizumab group. 
Even though ranibizumab has a theoretically better ability 
to penetrate through the retina and RPE to the choroidal 
vascular abnormalities of PCV [16,18], there was no signifi-
cant difference in polypoidal complex regression between 
the two groups. The location of the PCV vessels beneath 
the RPE may prevent sufficient penetration of anti-VEGF 
drugs to induce PCV regression. This result suggests that 
PCV may be a different inner choroidal vascular abnor-
mality [19,20] and not just a variant of choroidal neovascu-
larizatoin (CNV). 
In recent studies, PDT has shown good results in reduc-
tion of leakage and regression of polyps in PCV eyes [5,6]. 
Particularly, in the EVEREST study, the first randomized 
and prospective study of PCV treatment, a PDT combina-
tion of ranibizumab and PDT monotherapy was effective 
in completely regressing polyps at month 6 than was ra-
nibizumab monotherapy. However, there was no significant 
difference in improvement of visual acuity from baseline 
between PDT combination with the ranibizumab group 
and the ranibizumab monotherapy group. In addition, se-
vere visual loss due to extensive subretinal hemorrhage is 
not uncommon after PDT [21], and PDT itself can result in 
a temporary increase in VEGF [14]. 
In terms of visual outcome, despite weakness in polyp 
regression, anti-VEGF monotherapy could be considered 
for PCV in cases with minimal polyp lesions or in cases 
with only a branching vascular network. We await long-
term results of the EVEREST trial, which can confirm 
which modality is superior for treatment of PCV. More 
clinical and basic science studies are necessary to clarify 
the pathogenesis of PCV and to provide therapeutic guide-
lines.
Because of the retrospective nature of the study the in-
herent bias that exists in this study. And because the treat-
ment choice was left to the discretion of the patient and 
treating physician, some potential for bias does exist. How-
ever, in our institute, the preferred PCV treatment with 
anti-VEGF (except for PDT) shifted from bevacizumab to 
ranibizumab from 2008 to 2009. Almost all patients were 
treated with bevacizumab from 2008 to the first half of 
2009 and with ranibizumab from the second half of 2009 
to date. As a result, this study could be more compara-
tive. Moreover, the similarity in baseline characteristics 
between the two groups suggests that the groups were well 
balanced. Another limitation in this study was the absence 
of a strict protocol for measuring visual acuity, which led 
to some of the variances in visual acuity that were noted 
in the two groups and may limit interpretation of these vi-
sual acuity results. However, we were able to significantly 
identify trends in visual improvement after anti-VEGF 
injection for PCV eyes. A planned randomized, controlled 
study would be necessary for a more precise determination 
of the differences between these two treatments.
In summary, bevacizumab and ranibizumab have simi-
lar effects on stabilization of visual acuity and macular 
edema with PCV eyes in the short term. However, ranibi-
zumab appears to be superior to bevacizumab with regard 
to short-term ability to decrease exudation. Additionally, 
there is a trend suggesting that ranibizumab may also 
provide superior visual acuity. Although this study could 
not provide definite proof that there were significant dif-
ferences in the visual acuity as result of PCV eyes treated 
with bevacizumab or ranibizumab, these results appear to 
demonstrate a possible difference in the biologic activities 
of the two anti-VEGF agents. These results should be con-
sidered clinically when performing combination therapy 
with PDT or when deciding on a course of anti-VEGF 
agent for treatment of PCV eyes. 
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